München
05.12.25 | 08:03
0,928 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| DIAMYD MEDICAL Aktie jetzt für 0€ handeln | |||||
| Do | Bulletin from Annual General Meeting of Diamyd Medical AB | 2 | Cision News | ||
| Di | DIAMYD MEDICAL AB: Annual Report 2024/2025 | 5 | Cision News | ||
| 14.11. | Diamyd Medical AB: Diamyd Medical's pivotal Phase 3 Type 1 Diabetes trial clears last safety review ahead of early readout in March 2026 | 544 | PR Newswire | STOCKHOLM, Nov. 14, 2025 /PRNewswire/ -- The independent Data Safety Monitoring Board (DSMB) has completed its sixth scheduled safety review of Diamyd Medical's registrational Phase... ► Artikel lesen | |
| 13.11. | Diamyd Medical AB Ser. B Full Year Sales Decline | 1 | RTTNews | ||
| 13.11. | DIAMYD MEDICAL AB: Information about the Annual Report 2024/2025 | 1 | Cision News | ||
| 12.11. | DIAMYD MEDICAL AB: Diamyd Medical marks World Diabetes Day with expert panel on the future of Type 1 Diabetes treatment | 3 | Cision News | ||
| 08.10. | Diamyd Medical AB Ser. B Q4 Loss Widens | - | RTTNews | ||
| 08.10. | DIAMYD MEDICAL AB: Year-End Report 24/25 | 1 | Cision News | ||
| 08.10. | Diamyd Medical AB (publ): Year-End Report 24/25 | 211 | GlobeNewswire (Europe) | September 2024 - August 2025, Diamyd Medical AB (publ), Fiscal year 2024/2025
Precision Medicine for Type 1 Diabetes
Aiming for Accelerated Market Approval
Diamyd Medical develops a proprietary platform... ► Artikel lesen | |
| 03.10. | DIAMYD MEDICAL AB: Hong Kong grants precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes | 1 | Cision News | ||
| 03.10. | Diamyd Medical AB (publ): Hong Kong grants precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes | 125 | GlobeNewswire (Europe) | Diamyd Medical has been granted a patent in Hong Kong protecting the use of insulin-based antigens to treat individuals with type 1 diabetes carrying the HLA DR4-DQ8 genetic marker. The patent is valid... ► Artikel lesen | |
| 11.09. | DIAMYD MEDICAL AB: New analysis to be presented at EASD supports potential of Diamyd to delay the progression of Stage 3 Type 1 Diabetes | 2 | Cision News | ||
| 10.09. | DIAMYD MEDICAL AB: Eurasia to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes | 2 | Cision News | ||
| 10.09. | Diamyd Medical AB (publ): Eurasia to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes | 140 | GlobeNewswire (Europe) | The Eurasian Patent Office has informed Diamyd Medical that the patent application protecting the use of insulin-based antigens for the treatment of individuals with type 1 diabetes carrying the HLA... ► Artikel lesen | |
| 05.09. | DIAMYD MEDICAL AB: ASSET partnership, coordinated by Diamyd Medical, organizes 2[nd] annual Type 1 Diabetes screening conference | 1 | Cision News | ||
| 22.07. | DIAMYD MEDICAL AB: Diamyd Medical releases the full video recording from a panel discussion at the ADA meeting in June | 1 | Cision News | ||
| 25.06. | DIAMYD MEDICAL AB: Quarterly Report 3 24/25 | 2 | Cision News | ||
| 25.06. | Diamyd Medical AB (publ): Quarterly Report 3 24/25 | 204 | GlobeNewswire (Europe) | Precision Medicine for Autoimmune Diabetes
Aiming for Accelerated Market Approval
Autoimmune or Type-1 Diabetes (T1D) is a progressive disease, diagnosed as at least two antibodies to the insulin producing... ► Artikel lesen | |
| 16.06. | DIAMYD MEDICAL AB: Diamyd Medical to participate in two key US diabetes events | 11 | Cision News | ||
| 19.05. | Diamyd Medical AB (publ): Diamyd Medical appoints Niklas Axelsson as CFO | 181 | GlobeNewswire (Europe) | Niklas Axelsson has been appointed CFO of Diamyd Medical. He will assume his position in August and will also join the management team. Niklas Axelsson brings more than 25 years of experience across... ► Artikel lesen |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 41,305 | +0,15 % | Novo Nordisk Aktie: Das große Trendwende-Szenario? | Wo kann die Novo Nordisk Aktie ihre massive Baisse stoppen? Ein neuer Versuch könnte in der vergangenen Woche gestartet worden sein mit einer deutlichen Intraday-Erholung am Montag vom Baissetief bei... ► Artikel lesen | |
| PFIZER | 22,345 | -0,02 % | Pfizer-Aktie: Darum bleibt sie ein Kauftipp! | Pfizer kämpft seit dem Ende des pandemiebedingten Höhenflugs mit einem deutlichen Kursrückgang. Die während der COVID-Jahre erwirtschafteten Rekordmittel wurden nicht wie erhofft in nachhaltiges Wachstum... ► Artikel lesen | |
| ABBVIE | 194,80 | +0,31 % | AbbVie: Pharmaunternehmen vor möglichem Breakout? | AbbVie zeigt sich in einem stabilen technischen Umfeld und konsolidiert über wichtigen Durchschnittslinien. Könnte ein möglicher Breakout bevorstehen Den vollständigen Artikel lesen ... ► Artikel lesen | |
| ABBOTT LABORATORIES | 107,24 | -0,11 % | Medtronic Launches MiniMed 780G In U.S. With Abbott's New Instinct CGM Sensor | DUBLIN (dpa-AFX) - Medtronic (MDT) has begun the full U.S. rollout of the MiniMed 780G insulin delivery system integrated with Abbott's Instinct sensor, following FDA clearance earlier this... ► Artikel lesen | |
| ZOETIS | 101,62 | -0,27 % | Zoetis Stock Plummets 24.8% YTD: Here's What You Need to Know | ||
| AXSOME THERAPEUTICS | 129,15 | +0,78 % | Axsome Therapeutics, Inc.: Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy | Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABAA a2,3 receptor positive allosteric modulator Deepens Axsome's broad and innovative neuroscience portfolio with a synergistic... ► Artikel lesen | |
| DAIICHI SANKYO | 19,285 | +0,55 % | Daiichi Sankyo receives FDA untitled letter taking aim at Turalio patient ambassador video | ||
| TRULIEVE CANNABIS | 5,160 | -1,15 % | CSE Bulletin: Redemption - Trulieve Cannabis Corp. 6OCT2026 Notes (TRUL.NT.U) | Toronto, Ontario--(Newsfile Corp. - Le 3 décembre/December 2025) - Trulieve Cannabis Corp. ("Trulieve"), has announced it has issued a notice of redemption for all of its outstanding 8.0% senior... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 23,520 | -0,21 % | Acadia Pharmaceuticals stock price target raised by Mizuho to $29 | ||
| CATALYST PHARMACEUTICALS | 19,670 | -2,62 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 62,34 | -1,45 % | How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint | ||
| TG THERAPEUTICS | 26,610 | -2,88 % | TG Therapeutics, Inc.: TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI | NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated... ► Artikel lesen | |
| CNBX PHARMACEUTICALS | - | - | CNBX Pharmaceuticals Inc. - 10-K, Annual Report | ||
| AURINIA PHARMACEUTICALS | 13,060 | -2,61 % | Wachstumssorgen: Leerink Partners stuft Aurinia Pharmaceuticals herab | ||
| CAMURUS | 55,75 | +1,27 % | AKTIONÄR-Tipp Camurus: Gamechanger im Adipositas-Markt? Kurssprung! | Der Adipositas-Markt zählt innerhalb der Biopharma-Branche weiterhin zu den heißesten Bereichen - nicht zuletzt durch den Bieterkampf zwischen Pfizer und Novo Nordisk um Metsera. Unlängst verschiebt... ► Artikel lesen |
DIAMYD MEDICAL AB gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,928 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAMYD MEDICAL AB finden Sie auf Wallstreet Online.